pLOG

2024-02-16

Biopharmaceutical Industry's PSP Development Report: Key Findings Revealing Future Trends

The biopharmaceutical industry is undergoing a transformation, particularly in the field of Patient Support Programs (PSP). Based on a collaboration between CardinoHealth and BioPharma Dive, a survey targeting 150 biopharmaceutical executives and consultants reveals three key conclusions, highlighting the rapid development of PSP in today's pharmaceutical industry.

1.Primary Focus on Who to Help

Nearly half of the respondents consider determining eligibility for PSP participation as one of the most important goals. This indicates that pharmaceutical companies are increasingly focused on ensuring that PSP genuinely benefits those in need. In the past, PSP may have been about expanding coverage broadly, but now there is more emphasis on specific cases and individualized needs. This means that pharmaceutical companies need to more accurately identify which patients can benefit from PSP to ensure appropriate resource allocation. This shift implies that PSP is no longer just a prescription supplement but rather a comprehensive plan that cares about patient needs.

2.The Crucial Role of Data Collection

The survey indicates that data collection for PSP has expanded from past content limited to patient-side to integrating workflows on the medical side. This means that pharmaceutical companies can obtain more comprehensive and rich information about patient journeys, which is crucial for providing better support. Automated data collection technology is also becoming increasingly important to ensure the accuracy and timeliness of information. This will help improve the efficiency of PSP and make it more responsive to patient needs. Therefore, PSP not only needs rich data but also modern technology to ensure the effective utilization of information.

3.The Importance of Intermediary Services

PSP services act as intermediaries in the patient journey, providing valuable internal perspectives to biopharmaceutical companies and going beyond the value of just providing medication. One future trend is more patient involvement in determining PSP service content, making PSP more personalized and closer to actual needs. This also means that biopharmaceutical companies need to be more flexible and open to meet patient participation and contribution. Intermediary services are not only about providing information but also about building interaction and trust between patients and pharmaceutical companies.

In summary, the biopharmaceutical industry is actively transforming, and Patient Support Programs (PSP) are one of the important drivers of this transformation. Ensuring that PSP truly helps those in need relies on determining eligibility, extensive data collection, and providing intermediary services. This transformation not only affects pharmaceutical companies but also has profound implications for public health and quality of life. Therefore, pharmaceutical companies need more innovative and individualized approaches to ensure that PSP maximally meets patient needs, thereby improving treatment outcomes, enhancing quality of life, and paying more attention to patient needs and expectations. This transformation is both a challenge and an opportunity to care more about and support our health.

Chief Operation Office of PATIENTSFORCE ,Evie Wang

evie.wang@media-wind.com.tw

Reference: